Evoke Wealth’s ImmunityBio IBRX Stock Holding History

Evoke Wealth’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100	Closed	-$379	–	1240
2019 Q4	$379	Buy	+100	New	+$170	﹤0.01%	1204

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Evoke Wealth's IBRX Position: Q1 2020 in Review

Evoke Wealth sold out of ImmunityBio (IBRX) in Q1 2020, closing a stake of 100 shares — an estimated $379 sold.

Evoke Wealth first reported a position in IBRX in Q4 2019 and held it in 1 quarter. The position peaked at $379 in Q4 2019. 49 funds tracked by Wall St. Rank hold IBRX as of Q1 2020.

Evoke Wealth reported no remaining ImmunityBio position as of Q1 2020 after selling out during the quarter.
Evoke Wealth sold 100 ImmunityBio shares in Q1 2020, an estimated $379.
Evoke Wealth first reported a position in ImmunityBio in Q4 2019 and held it in 1 quarter.
Evoke Wealth's ImmunityBio position peaked at $379 in Q4 2019.
49 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2020.

Based on Evoke Wealth's 13F filing for Q1 2020, filed 7 May 2020.